The problem adyn is actually solving
Most people try four or more birth control methods before finding one that works. That's years of unpleasant surprises — mood swings you didn't expect, bleeding patterns nobody warned you about, or sexual side effects that make you question whether contraception is worth it at all.
adyn's approach is straightforward: test your hormones and genetic markers upfront, then use that data to recommend methods that match your biology. It's precision medicine for birth control, and it addresses a real gap in how contraception gets prescribed today. Instead of starting with whatever your provider defaults to (usually the pill they have samples for), you get personalized guidance based on how your body actually processes hormones.
The core insight is solid. Birth control side effects aren't random — they correlate with hormone profiles and genetic factors that are testable. Knowing someone's baseline estrogen metabolism or clotting risk markers before prescribing saves them from preventable problems.
Three areas where the precision could get even more precise
The genetic and hormone testing is doing exactly what it should. But there are three common side effect categories where users still seem to be discovering problems after the fact, when prediction would be more valuable.
Sexual side effects deserve first-class prediction. Loss of libido and vaginal dryness are showing up repeatedly as deal-breakers — the kind of side effects that make people consider abandoning birth control entirely despite needing contraception. These aren't minor inconveniences; they're relationship-impacting symptoms that users describe as forced trade-offs. The data to predict sexual dysfunction risk exists in hormone profiles and formulation types. A clear upfront alert system would help users make informed decisions about methods before experiencing these effects.
Mental health screening should be mandatory in onboarding. Depression and anxiety from hormonal birth control follow a consistent pattern: symptoms develop gradually, get attributed to life stress, and only get connected to contraception after stopping. Providers often miss this during regular check-ins because patients minimize symptoms. Adding structured mental health history screening to the intake flow — then using that to flag contraindicated formulations during consultation — would close a gap that standard care consistently misses.
Bleeding pattern forecasts would prevent the most common discontinuation reason. Breakthrough bleeding and irregular cycles are common enough to drive method abandonment, yet users consistently report being unprepared for these changes. The patterns are predictable based on formulation type and baseline hormones. Showing month-by-month bleeding forecasts for each recommended method would shift that discovery from after insertion (when switching is hardest) to the decision stage (when it's most useful).
The bigger picture
What makes adyn's model compelling is that it takes existing medical knowledge about hormone metabolism and genetic risk factors and puts it to work before prescription rather than after problems emerge. The opportunity now is to extend that same proactive approach to the side effect categories that most commonly derail contraception: sexual function, mental health, and bleeding changes.
These aren't problems with the core product — they're opportunities to make the precision medicine approach even more comprehensive. The infrastructure is already there: testing, provider consultation, personalized recommendations. Adding predictive guidance for these high-impact outcomes would ensure users go into their birth control choice with genuinely complete information.
We used Mimir to analyze adyn's public presence and user feedback for this teardown. The patterns were remarkably consistent: people want the trial-and-error cycle to end, and they're willing to test upfront to make that happen. They just need the predictions to cover all the ways birth control commonly fails, not just some of them.